2026-08-31T16:09:45.05Z / 路透社
记者：史蒂夫·霍兰德斯与迈克尔·厄曼
2026年8月31日 世界协调时16:09 更新于12分钟前
[1/2]美国商务部长霍华德·卢特尼克、美国卫生与公众服务部长小罗伯特·F·肯尼迪，以及美国医疗保险和医疗补助服务中心（CMS）署长穆罕默德·奥兹博士站在美国总统唐纳德·特朗普身后，特朗普正在白宫椭圆形办公室就其政府的医疗政策发表讲话，华盛顿特区，美国，2026年8月31日。路透社/伊芙琳·霍克斯坦
完整报道请点击此处
- 与梯瓦、CSL、安斯泰来及多家小型生物技术公司签署新协议
- 路透社此前曾报道，小型药企参与此类协议的经济激励有限
- 美国处方药价格往往是其他发达国家的近三倍
华盛顿8月31日电（路透社）——美国总统唐纳德·特朗普周一宣布与国际制药公司及部分小型生物技术公司达成新一轮药品定价协议，这是其推动降低美国民众医疗负担举措的一部分。
特朗普与相关药企高管在椭圆形办公室的活动中表示，已与包括安斯泰来、比昂医药、CSL、BridgeBIO、太阳药业、梯瓦以及UCB SA在内的九家公司签署协议。这些公司将以最惠国价格向州医疗补助计划供应药品，特朗普称此举“力度极大的折扣，将大幅降低你的医疗护理成本”。
订阅《每日案卷》新闻简报，将最新法律资讯直接发送至您的收件箱，开启您的晨间资讯。点击此处注册。
广告 · 继续滚动阅读
美国患者目前在处方药上的花费遥遥领先于其他国家，往往是其他发达国家的近三倍，特朗普一直向制药商施压，要求其将药品价格降至与其他国家患者支付水平相当的程度。
此次协议将延续特朗普政府去年起与包括辉瑞、礼来和安进在内的全球17家大型制药商达成的协议框架。这些制药商同意提供与其他发达国家定价相当的低价，即所谓的“最惠国”定价。
这些公司同意为联邦医疗项目降低部分药品价格，并通过特朗普旗下网站直接向患者销售部分药品，以此换取关税减免。
小型药企迟迟未签署协议
路透社此前曾报道，中小型制药商在签署药品定价协议方面进展缓慢。
路透社6月的一篇报道显示，截至当时仅有日本的安斯泰来确认申请加入医疗补助定价计划，伊奥尼斯制药等公司的高管表示，他们认为参与此类协议几乎没有经济收益。
目前尚不清楚这些协议将为政府或患者节省多少开支。根据现行法律，医疗补助计划已从制药商处获得大幅折扣，且该计划覆盖的大多数患者自付处方药费用极低。
今年以来，白宫已多次与制药业高管举办高调活动，宣传其在医疗成本控制方面的努力，这是其在今年决定国会控制权的中期选举前突出民生负担议题整体举措的一部分。
blob:https://www.reuters.com/65a45596-880f-4f4c-9c48-2eb4fe1ceb1f
https://www.reuters.com/legal/litigation/trump-administration-announce-drug-pricing-deals-2026-08-31/
美国政府表示，其更广泛的药品定价举措，包括此前与大型制药公司达成的协议，未来十年可为联邦和州政府节省643亿美元开支，但这一数字尚未得到证实。
广告 · 继续滚动阅读
additional reporting by Kamal Choudhury and Sriparna Roy in Bengaluru and Yasmeen Abutaleb in Washington; Editing by Caroline Humer and Bill Berkrot
我们的准则：汤森路透信任原则。
Trump administration announces drug pricing deals with Teva, Astellas and others
2026-08-31T16:09:45.05Z / Reuters
By Steve Holland and Michael Erman
August 31, 2026 4:09 PM UTC Updated 12 mins ago
Item 1 of 2 U.S. Secretary of Commerce Howard Lutnick, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., and U.S. Center for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz stand behind U.S. President Donald Trump, as he delivers remarks on his administration’s healthcare policies, in the Oval Office at the White House in Washington, D.C., U.S., August 31, 2026. REUTERS/Evelyn Hockstein
[1/2]U.S. Secretary of Commerce Howard Lutnick, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., and U.S. Center for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz stand behind U.S. President Donald Trump, as he delivers remarks on his administration’s healthcare… Read more
- New agreements signed with Teva, CSL, Astellas, some smaller biotechs
- Reuters previously reported smaller drugmakers see limited financial incentive to participate
- US prescription drug costs often nearly triple those of other developed nations
WASHINGTON, Aug 31 (Reuters) – U.S. President Donald Trump announced a new round of drug-pricing agreements with international pharmaceutical companies and some smaller biotechs on Monday, part of a push to make healthcare more affordable for Americans.
Deals were signed with nine companies including Astellas, BeOne Medicines, CSL, BridgeBIO, Sun Pharmaceutical, Teva and UCB SA.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Advertisement · Scroll to continue
These companies have offered drugs to state Medicaid programs at most-favored-nation prices, Trump said in an Oval Office event with executives of the companies, describing this as “a tremendous discount, which should bring down the cost of your medical care by tremendous amounts.”
U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.
The deals will build on agreements the administration struck with 17 of the world’s largest drugmakers, including Pfizer, Eli Lilly and Amgen, starting last year. The drugmakers agreed to offer lower prices comparable to what is paid in other developed countries, referred to as “most-favored-nation” pricing.
Advertisement · Scroll to continue
Those companies agreed to cut some prices for federal health programs and sell some medicines directly to patients through a Trump-branded website, in return for tariff relief.
SMALL DRUGMAKERS HAVE DELAYED DEALS
Smaller and mid-sized drugmakers had been slow to sign onto drug-pricing deals, Reuters has reported.
A Reuters report in June found that only Japan’s Astellas had confirmed applying for the Medicaid pricing program by that point, with executives at companies such as Ionis Pharmaceuticals saying they saw little financial benefit in joining.
It is not yet clear how much the deals will save the government or patients. Medicaid already gets steep discounts from drugmakers under existing law, and most people covered by the program pay little out of pocket for prescriptions.
The White House has held several high-profile events with pharmaceutical executives this year to promote its efforts on healthcare costs, part of a broader push to highlight affordability before this year’s midterm elections that will decide control of Congress.
blob:https://www.reuters.com/65a45596-880f-4f4c-9c48-2eb4fe1ceb1f
https://www.reuters.com/legal/litigation/trump-administration-announce-drug-pricing-deals-2026-08-31/
The administration has said its broader drug pricing push, including the earlier deals with large pharmaceutical companies, could save $64.3 billion in federal and state spending over the next decade, but that number is speculative.
Advertisement · Scroll to continue
Additional reporting by Kamal Choudhury and Sriparna Roy in Bengaluru and Yasmeen Abutaleb in Washington; Editing by Caroline Humer and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
发表回复